• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants

tetano

Editor, Senior Moderator
J Med Virol


. 2024 Jan;96(1):e29314.
doi: 10.1002/jmv.29314. Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants

Ziteng Liang[SUP] 1 2 [/SUP], Jincheng Tong[SUP] 2 [/SUP], Ziqi Sun[SUP] 2 [/SUP], Shuo Liu[SUP] 1 3 [/SUP], Jiajing Wu[SUP] 4 [/SUP], Xi Wu[SUP] 2 [/SUP], Tao Li[SUP] 2 [/SUP], Yuanling Yu[SUP] 3 [/SUP], Li Zhang[SUP] 2 [/SUP], Chenyan Zhao[SUP] 2 [/SUP], Qiong Lu[SUP] 2 [/SUP], Jianhui Nie[SUP] 2 [/SUP], Weijin Huang[SUP] 2 [/SUP], Youchun Wang[SUP] 1 2 3 5 [/SUP]



Affiliations
Abstract

SARS-CoV-2 breakthrough infections in vaccinated individuals underscore the threat posed by continuous mutating variants, such as Omicron, to vaccine-induced immunity. This necessitates the search for broad-spectrum immunogens capable of countering infections from such variants. This study evaluates the immunogenicity relationship among SARS-CoV-2 variants, from D614G to XBB, through Guinea pig vaccination, covering D614G, Alpha, Beta, Gamma, Delta, BA.1, BA.2, BA.2.75, BA.2.75.2, BA.5, BF.7, BQ.1.1, and XBB, employing three immunization strategies: three-dose monovalent immunogens, three-dose bivalent immunogens, and a two-dose vaccination with D614G followed by a booster immunization with a variant strain immunogen. Three distinct immunogenicity clusters were identified: D614G, Alpha, Beta, Gamma, and Delta as cluster 1, BA.1, BA.2, and BA.2.75 as cluster 2, BA.2.75.2, BA.5, BF.7, BQ.1.1, and XBB as cluster 3. Broad-spectrum protection could be achieved through a combined immunization strategy using bivalent immunogens or D614G and XBB, or two initial D614G vaccinations followed by two XBB boosters. A comparison of neutralizing antibody levels induced by XBB boosting and equivalent dosing of D614G and XBB revealed that the XBB booster produced higher antibody levels. The study suggests that vaccine antigen selection should focus on the antigenic alterations among variants, eliminating the need for updating vaccine components for each variant.

Keywords: SARS-CoV-2; bivalent immunogens; booster immunization; immunogenicity relationship; monovalent immunogens.

 
Back
Top Bottom